Prenolica

Prenolica is an Australian biopharmaceutical company specializing in the development and commercialization of "Bioeffectives," a unique class of biologically active substances extracted from conifer green biomass. Formerly known as Solagran Limited, the company utilizes patented "soft" extraction technology to isolate synergistic complexes of polyprenols and other "live elements" without damaging their biological activity. Its lead pharmaceutical product, Ropren (Bioeffective R), is a registered treatment for chronic liver diseases, including NASH and cirrhosis, in Russia. Prenolica also markets a range of TGA-approved therapeutic products in Australia and Southeast Asia focused on gastrointestinal health, immunity, and antioxidant support. The company's research pipeline extends into neurodegenerative disorders such as Alzheimer's disease and metabolic conditions, leveraging over 80 years of foundational Russian forest biochemistry research.